Research Training in Gastroenterology and Hepatology

T32 DK 067872的竞争性更新申请，胃肠病学和肝病学研究培训， 代表马里兰州，巴尔的摩（UMB）的大学提交，要求5年的支持3博士预科 4名博士后（MD、PhD、MD/PhD）。该计划的目标是寻找和准备有才华的学员， 研究和/或领导职业在学术界，政府，或通过提供一个综合的，跨 学科课程，强调基础或临床和转化科学培训的三个主要之一 实质性领域：（1）胃肠道粘膜生物学和信号传导，（2）肠道微生物组，免疫学和遗传学， （3）肝胆疾病。由教师导师代表的UMB实体拥有强大的联邦资金 投资组合跨越学校，部门和有组织的研究中心和研究所，包括学校 医学（内科，儿科，外科，流行病学和公共卫生，微生物学和 免疫学，生物化学和分子生物学）和药学（药物科学系）， 疫苗开发与全球健康中心和基因组科学研究所。全面 培训机会允许博士前学员获得博士或MD/博士学位，博士后学员 获得MS，MPH或博士学位。在专家导师的监督下，该培训计划旨在 使受训者能够发展假设，设计和执行基础或临床研究，以测试这些假设， 成为至少一个与消化或肝脏疾病相关的实质性领域的专家， 演讲技巧，掌握负责任的研究行为的原则，并准备过渡到职业生涯 主要研究胃肠道和肝胆系统的生物学和病理学。基础和临床 在三个重点领域（GI粘液生物学和信号传导;肠道微生物组， 免疫学和遗传学;肝胆疾病），是由有成就的，富有成效的经验， 在研究轨道内和研究轨道之间互动的导师。自2005年成立以来，该T32计划已 非常成功;所有的培训名额都得到了持续的填补，学员保留率达到100%， 从出版物、授予高级学位和职业成果来衡量，这一成绩是非常出色的。所有 完成培训的博士前学员有资格获得博士学位，几乎所有的MD博士后学员 已经或即将获得高级学位（MS，MPH或PhD）。这个T32项目仍然非常 多样化，满足社会需要，以纠正生物医学研究和学术界的代表性不足;三分之二 我们的受训人员中有五分之一是女性，五分之一是拉丁美洲人或非洲裔美国人。前受训人员获得 教师任命或执行研究的联邦机构（NIH和FDA）或行业，竞争成功 获得联邦资助，并在学术界获得领导地位。值得注意的是，通过吸引有才华的受训人员， 调查人员从其他学科的基础和以病人为中心的消化系统疾病和肝脏研究，这T32 该计划为UMB临床，教育和科学界增添了巨大价值。

This competitive renewal application for T32 DK067872, Research Training in Gastroenterology and Hepatology, submitted on behalf of the University of Maryland, Baltimore (UMB) requests 5 years of support for 3 predoctoral and 4 postdoctoral (MD, PhD, MD/PhD) trainees. Program goals are to seek and prepare talented trainees for research and/or leadership careers in academia, government, or industry by offering an integrated, inter- disciplinary curriculum that emphasizes basic or clinical & translational science training in one of three major substantive areas: (1) gastrointestinal mucosal biology & signaling, (2) gut microbiome, immunology & genetics, and (3) hepatobiliary disorders. UMB entities represented by faculty mentors with robust federal funding portfolios cut across schools, departments, and organized research centers and institutes to include the Schools of Medicine (Departments of Medicine, Pediatrics, Surgery, Epidemiology & Public Health, Microbiology & Immunology, Biochemistry & Molecular Biology) and Pharmacy (Department of Pharmaceutical Sciences), the Center for Vaccine Development & Global Health, and the Institute for Genome Sciences. Comprehensive training opportunities allow predoctoral trainees to obtain PhD or MD/PhD degrees and postdoctoral trainees to earn MS, MPH or PhD degrees. Under the supervision of expert mentors, this training program is designed to enable trainees to develop hypotheses, design and perform basic or clinical research to test these hypotheses, become expert in at least one substantive area relevant to digestive or liver diseases, develop oral and written presentation skills, master the principles of responsible conduct of research, and prepare for transition to careers focused on the study of the biology and pathobiology of the GI tract and hepatobiliary system. Basic and clinical & translational science training in three focus areas (GI Mucosal Biology & Signaling; Gut Microbiome, Immunology & Genetics; Hepatobiliary Disorders), is directed by accomplished, highly productive experienced mentors who interact both within and amongst research tracks. Since its inception in 2005, this T32 program has been highly successful; all training slots were consistently filled, trainee retention was 100%, and productivity as measured by publications, awarding of advanced degrees, and career outcomes has been exceptional. All predoctoral trainees who completed training qualified for the PhD degree and nearly all MD postdoctoral trainees either have or will be awarded advanced degrees (MS, MPH, or PhD). This T32 program remains extraordinarily diverse, fulfilling a societal need to redress underrepresentation in biomedical research and academia; two-thirds of our trainees are women and one-fifth are Latino or African American. Former trainees obtained academic faculty appointments or perform research for federal agencies (NIH and FDA) or industry, competed successfully for federal funding, and attained leadership positions in academia. Notably, by attracting talented trainees and investigators from other disciplines to basic and patient-centered digestive diseases and liver research, this T32 program adds great value to the UMB clinical, educational and scientific community.